Oncolytics Biotech® Inc : Oncolytics Biotech s® Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Oncolytics Biotech s (ONCY) Pelareorep Selected for Inclusion in Precision PromiseSM Pivotal Phase 3 Platform Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Adaptive clinical trial designed to accelerate registration pathways for pancreatic cancer therapies and expected to reduce cost of a Phase 3 study for pelareorep by ~50% compared to a traditional trial
If successful, new clinical study expected to supp.
/PRNewswire/ The Pancreatic Cancer Action Network (PanCAN), a leading pancreatic cancer patient advocacy organization, today launched its Call on Congress.
/PRNewswire/ A new survey1 reveals that the majority of pet parents in the U.S. are prepared to evacuate their homes with their pets in case of an immediate.